Bruce L. Levine, Ph.D.
Bruce L. Levine, Ph.D.
Research Associate Professor of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Contact information
M6.40 Maloney Building
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104-4268
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104-4268
Office: (215)-573-6788
Fax: 215-615-4718
Fax: 215-615-4718
Email:
levinebl@mail.med.upenn.edu
levinebl@mail.med.upenn.edu
Links
Clinical Cell and Vaccine Production Facility, Bruce Levine, Ph.D., Director
Abramson Family Cancer Research Institute, Bruce Levine, Ph.D. Biography and research description
Clinical Cell and Vaccine Production Facility, Bruce Levine, Ph.D., Director
Abramson Family Cancer Research Institute, Bruce Levine, Ph.D. Biography and research description
Education:
B.A. (Major-Biology, Minor-History)
The University of Pennsylvania , 1984.
Ph.D. (Immunology and Infectious Diseases)
The Johns Hopkins University, 1992.
Permanent linkB.A. (Major-Biology, Minor-History)
The University of Pennsylvania , 1984.
Ph.D. (Immunology and Infectious Diseases)
The Johns Hopkins University, 1992.
Description of Research Expertise
Immunology, Cell and Gene TherapyDescription of Other Expertise
Good Manufacturing PracticesSelected Publications
Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH: Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science Translational Medicine 4(132): 132ra53, May 2012.Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ: HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer January 2012 Notes: doi: 10.1002/cncr.26734. [Epub ahead of print]
Koski, GK, Koldovsky, U, Xu, S, Mick, R, Sharma, A, Weinstein, S, Nisenbaum, H, Levine, BL, Fox, K, Zhang, P, Czerniecki, BJ: A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. Journal of Immunotherapy 35(1): 54, January 2012 Notes: Epub ahead of print November, 2011.
Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR: Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood January 2012 Notes: Epub ahead of print.
Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, Levine BL, June CH, Medin JA, Fowler DH: The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells. Science Translational Medicine 3(111): 111ra120, November 2011.
Hardy NM, Mossoba ME, Steinberg SM, Fellowes V, Yan XY, Hakim FT, Babb RR, Avila D, Gea-Banacloche J, Sportès C, Levine BL, June CH, Khuu HM, Carpenter AE, Krumlauf MC, Dwyer AJ, Gress RE, Fowler DH, Bishop MR: Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer. Clinical Cancer Research 17(21): 6878, November 2011 Notes: Epub 2011 Sep 26.
Chiang CL, Maier DA, Kandalaft LE, Brennan AL, Lanitis E, Ye Q, Levine BL, Czerniecki BJ, Powell DJ Jr, Coukos G: Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. Journal of Translational Medicine 9(1): 198, November 2011 Notes: Epub ahead of print.
Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH: Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology and Immunotherapy October 2011 Notes: Epub ahead of print, DOI 10.1007/s00262-011-1081-8.
Porter DL, Levine BL, Kalos M, Bagg A, June CH: Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. New England Journal of Medicine 365(8): 725-33, August 2011 Notes: Epub 2011 Aug 10, accompanying Editorial "Redirecting T Cells" Urba WJ, Longo DL, PMID 21830939
Ye Q, Loisiou M, Levine BL, Suhoski MM, Riley JL, June CH, Coukos G, Powell DJ Jr.: Engineered Artificial Antigen Presenting Cells Facilitate Direct and Efficient Expansion of Tumor Infiltrating Lymphocytes. Journal of Translational Medicine 9(1): 131, August 2011.